In this issue:
Trastuzumab deruxtecan in HER2+ breast cancer with brain metastases
Hormonal contraceptive use and breast cancer (in situ) risk
Cost effectiveness of trastuzumab deruxtecan vs. emtansine in HER2+ metastatic breast cancer
21-gene recurrence score: impact on treatment decisions and costs in node positive breast cancer
Adherence to Dutch breast cancer survivor surveillance guidelines
Sacituzumab govitecan for hormone receptor+/HER2– metastatic breast cancer
Elacestrant for oestrogen receptor+/HER2– advanced breast cancer
QOL and health behaviours after adjuvant chemotherapy for breast cancer
Timing of postmastectomy RT after adjuvant chemotherapy in high-risk breast cancer
β-blockers and breast cancer survival
Please login below to download this issue (PDF)